Acelyrin

ACELYRIN's Phase 2b/3 trial of izokibep for uveitis failed to meet primary and secondary endpoints, leading to no further investment in izokibep. The company will focus on lonigutamab for thyroid eye disease, with a Phase 3 program set for Q1 2025. ACELYRIN's cash reserves are projected to fund operations until mid-2027.

ACELYRIN, INC. announced CFO Gil M. Labrucherie's resignation, with consulting services until March 2025. The Phase 2b/3 trial for izokibep in uveitis failed, halting further investment. Focus shifts to lonigutamab for thyroid eye disease, with a Phase 3 program in early 2025. Cash reserves support operations until mid-2027, enabling pipeline expansion.

ACELYRIN, INC. announced Phase 2b/3 trial of izokibep for uveitis did not meet primary or secondary endpoints. The company will focus on lonigutamab for thyroid eye disease, with Phase 3 trials starting Q1 2025. $562.4M in cash expected to fund operations until mid-2027.

ACELYRIN's Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet primary endpoint; company to focus on lonigutamab in thyroid eye disease, with Phase 3 program planned for Q1 2025.

The hidradenitis suppurativa market is projected to grow at a CAGR of 12.4% by 2034, driven by increased awareness, treatment access, biologic therapy approvals, and a robust pipeline. The market size in the 7MM was USD 1.4 billion in 2023, with approximately 6.2 million prevalent cases. Key companies and treatments include Incyte Corporation, AbbVie, MoonLake Immunotherapeutics, and therapies like Povorcitinib, RINVOQ, Lutikizumab, and Sonelokimab. Regulatory milestones and clinical trials are advancing, with potential market shifts expected from emerging therapies.

TD Cowen analyst Tyler Van Buren initiates Buy rating for ACELYRIN, INC. (SLRN) due to significant clinical trial progress and strategic focus on lead program. The company has completed Phase II study cohorts for lonigutamab in TED, with Phase III details expected soon. ACELYRIN, INC. is a clinical biopharma focusing on transformative medicines, with izokibep in Phase 3 trials for various conditions.

Acelyrin shifts focus from izokibep, despite positive PsA and HS trial results, to lonigutamab, a potential competitor to Amgen’s Tepezza for TED. Lonigutamab offers a subcutaneous advantage over Tepezza’s IV, with projected sales of $1.2 billion by 2038 amidst growing competition.